Expert Point of View: Robert Bruce Montgomery, MD


Get Permission

Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)

Formal discussant of this trial, Robert Bruce Montgomery, MD, Clinical Director of Genitourinary Medical Oncology, Seattle Cancer Alliance, said, “The rationale for checkpoint inhibition and [poly ADP--ribose polymerase (PARP)] inhibitors is strong in patients with underlying homologous recombination–deficient ovarian and breast cancers, but in patients who do not have underlying homologous repair deficiency, it’s a little less clear how PARP inhibition will actually help. You can’t generate a BRCA-ness signature by treating a nondeficient tumor with a PARP inhibitor,” he said.

“However, it has been shown that exposure to a PARP inhibitor will increase [programmed cell death ligand 1] expression, and in preclinical models, that does, in fact, lead to better responses with these various therapies,” Dr. Montgomery continued.

“The responses and progression-free survival were compelling in this early study, especially in view of the limited toxicity, although the high frequency of homologous recombination tumors limits the interpretation,” he concluded. ■

DISCLOSURE: Dr. Montgomery reported no conflicts of interest.


Related Articles

Small Study Evaluates Novel Combination in Metastatic Prostate Cancer

Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)

The combination of the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) produced positive preliminary...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.